News | Womens Cardiovascular Health | February 09, 2022

SCAI Releases Expert Consensus on Gender-specific Considerations in Myocardial Revascularization

Figure 1Recommended Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. ∗While not marketed in the United States, DCBs are available for clinical use in Canada, with 1-3 months of DAPT recommended. DAPT = dual antiplatelet therapy; LD, limited data. Reprinted from Capodanno D, Alfonso F, Levine GN, Valgimigli M, Angiolillo DJ. ACC/AHA versus ESC guidelines on dual antiplatelet therapy: JACC guideline comparison. J Am Coll Cardiol. 2018;72(23 Pt A):2915-2931, with permission from

February 9, 2022 — A newly released expert consensus statement on sex-specific considerations in myocardial revascularization aims to summarize available literature on myocardial revascularization in women and identify important gaps in evidence. The document was published today in the Journal of the Society for Cardiovascular Angiography & Interventions (JSCAI), the official journal of SCAI.

Cardiovascular disease is the leading cause of death and disability in women globally, claiming the lives of nearly 8.5 million women each year. Utilization of cardiovascular procedures is far lower in women than men, and women continue to be underrepresented in cardiovascular clinical trials, severely limiting the opportunity to better understand sex differences in cardiovascular drug or device outcomes. Current practice guidelines do not address gender-based differences and fail to highlight when insufficient evidence exists regarding cardiovascular outcomes in women, resulting in overall poorer outcomes.

“This consensus is an international collaborative effort that highlights the knowns, the gaps and ambiguities in evidence related to sex-specific revascularization,” said Alexandra Lansky, MD, FSCAI, Chair of the document, Professor of Medicine in the section of Cardiology at the Yale School of Medicine and a practicing cardiologist at Yale-New Haven Hospital. Lansky is also Editor-in-Chief of JSCAI.  “As a companion to the recent percutaneous coronary intervention (PCI) guidelines, it will inform clinicians on best practices most relevant to our female patients and draws attention to areas in need of additional evidence,” Lansky continued. 

The paper explores gaps in evidence in several areas including the epidemiology of ischemic heart disease, diagnostic tools to guide coronary revascularization, revascularization for chronic coronary syndromes, revascularization for non-ST-elevation myocardial infarction (MI) and ST-elevation MI, and revascularization consideration for specific patient populations, vascular access in women, and more.

“Physicians can use this consensus document to inform their discussions with female patients on the risks and benefits of coronary revascularization,” said J. Dawn Abbott, MD, FSCAI, Co-Chair of the document and Professor of Medicine and Director of the Interventional Cardiology Fellowship Training Program at Brown Medical School. “An understanding of the limitations of the data is important in this regard,” Abbott concluded. 

Authors of the paper state that while the evidence supporting clinical decisions in women is lacking, these findings are important to guide prospective investigation and establish research priorities. 

For more information: www.scai.org


Related Content

News | Cardiovascular Clinical Studies

April 9, 2026 — Mount Sinai researchers have created an analytic tool using machine learning that can predict ...

Home April 14, 2026
Home
News | Cardiovascular Clinical Studies

April 13, 2026 —The American Heart Association (AHA) has granted Case Western Reserve University the Rapid Impact ...

Home April 13, 2026
Home
News | Cardiovascular Clinical Studies

April 2, 2026 — Iterative Health and US Heart & Vascular (USHV) have announced a strategic partnership to advance ...

Home April 02, 2026
Home
News | Cardiovascular Clinical Studies

March 4, 2026 — UltraSight, a provider of AI-guided cardiac imaging workflows, has announced Late-Breaking clinical ...

Home March 04, 2026
Home
News | Cardiovascular Clinical Studies

Feb. 9, 2026 — HTA and MedAxiom have opened applications for the 2026 HeartX program, a cardiovascular-focused ...

Home February 18, 2026
Home
News | Cardiovascular Clinical Studies

Jan. 5, 2026 — Medera Inc., a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by ...

Home January 05, 2026
Home
News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 18, 2025 — (Newswise) It’s often mistaken for a heart attack, but Takotsubo cardiomyopathy — previously known as ...

Home August 21, 2025
Home
Subscribe Now